Annual EBITDA
-$43.54 M
-$18.02 M-70.58%
December 31, 2023
Summary
- As of February 12, 2025, ZVRA annual EBITDA is -$43.54 million, with the most recent change of -$18.02 million (-70.58%) on December 31, 2023.
- During the last 3 years, ZVRA annual EBITDA has fallen by -$38.11 million (-701.73%).
- ZVRA annual EBITDA is now -1158.08% below its all-time high of -$3.46 million, reached on December 1, 2013.
Performance
ZVRA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$29.30 M
-$13.11 M-81.03%
September 30, 2024
Summary
- As of February 12, 2025, ZVRA quarterly EBITDA is -$29.30 million, with the most recent change of -$13.11 million (-81.03%) on September 30, 2024.
- Over the past year, ZVRA quarterly EBITDA has dropped by -$10.95 million (-59.66%).
- ZVRA quarterly EBITDA is now -351.23% below its all-time high of $11.66 million, reached on June 1, 2016.
Performance
ZVRA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$78.22 M
-$19.53 M-33.28%
September 30, 2024
Summary
- As of February 12, 2025, ZVRA TTM EBITDA is -$78.22 million, with the most recent change of -$19.53 million (-33.28%) on September 30, 2024.
- Over the past year, ZVRA TTM EBITDA has dropped by -$34.68 million (-79.65%).
- ZVRA TTM EBITDA is now -38072.33% below its all-time high of $206.00 thousand, reached on March 1, 2022.
Performance
ZVRA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ZVRA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -70.6% | -59.7% | -79.7% |
| 3 y3 years | -701.7% | -59.7% | -79.7% |
| 5 y5 years | +11.5% | -59.7% | -79.7% |
ZVRA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -452.0% | at low | -522.2% | at low | <-9999.0% | at low |
| 5 y | 5-year | -701.7% | at low | -522.2% | at low | <-9999.0% | at low |
| alltime | all time | -1158.1% | +12.9% | -351.2% | at low | <-9999.0% | at low |
Zevra Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$29.30 M(+81.0%) | -$78.22 M(+33.3%) |
| Jun 2024 | - | -$16.18 M(+12.4%) | -$58.69 M(+30.8%) |
| Mar 2024 | - | -$14.39 M(-21.5%) | -$44.88 M(+3.1%) |
| Dec 2023 | -$43.54 M(+70.6%) | -$18.35 M(+88.0%) | -$43.54 M(+138.5%) |
| Sep 2023 | - | -$9.76 M(+311.6%) | -$18.25 M(+24.9%) |
| Jun 2023 | - | -$2.37 M(-81.8%) | -$14.62 M(-60.3%) |
| Mar 2023 | - | -$13.06 M(-288.2%) | -$36.79 M(+44.1%) |
| Dec 2022 | -$25.53 M(+223.6%) | $6.94 M(-213.3%) | -$25.53 M(-27.2%) |
| Sep 2022 | - | -$6.13 M(-75.0%) | -$35.06 M(+14.5%) |
| Jun 2022 | - | -$24.54 M(+1264.8%) | -$30.63 M(<-9900.0%) |
| Mar 2022 | - | -$1.80 M(-30.8%) | $206.00 K(-102.6%) |
| Dec 2021 | -$7.89 M(+45.2%) | - | - |
| Dec 2021 | - | -$2.60 M(+54.0%) | -$7.88 M(-6.8%) |
| Sep 2021 | - | -$1.69 M(-126.8%) | -$8.46 M(+5.7%) |
| Jun 2021 | - | $6.29 M(-163.7%) | -$8.00 M(-31.0%) |
| Mar 2021 | - | -$9.88 M(+211.0%) | -$11.60 M(+117.1%) |
| Dec 2020 | -$5.43 M(-69.4%) | -$3.18 M(+157.3%) | -$5.34 M(-14.8%) |
| Sep 2020 | - | -$1.24 M(-145.8%) | -$6.27 M(+1890.8%) |
| Jun 2020 | - | $2.70 M(-174.4%) | -$315.00 K(-97.0%) |
| Mar 2020 | - | -$3.63 M(-11.6%) | -$10.67 M(-39.8%) |
| Dec 2019 | -$17.73 M | -$4.11 M(-187.0%) | -$17.73 M(+4.3%) |
| Sep 2019 | - | $4.72 M(-161.7%) | -$16.99 M(-51.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | -$7.65 M(-28.4%) | -$35.07 M(-1.4%) |
| Mar 2019 | - | -$10.69 M(+217.1%) | -$35.56 M(-27.7%) |
| Dec 2018 | -$49.18 M(+37.5%) | -$3.37 M(-74.8%) | -$49.18 M(-9.7%) |
| Sep 2018 | - | -$13.36 M(+64.1%) | -$54.49 M(+10.8%) |
| Jun 2018 | - | -$8.14 M(-66.5%) | -$49.19 M(+7.7%) |
| Mar 2018 | - | -$24.31 M(+180.2%) | -$45.65 M(+27.7%) |
| Dec 2017 | -$35.76 M(+287.4%) | -$8.68 M(+7.7%) | -$35.76 M(+1.9%) |
| Sep 2017 | - | -$8.06 M(+75.0%) | -$35.10 M(-9.1%) |
| Jun 2017 | - | -$4.60 M(-68.1%) | -$38.60 M(+72.8%) |
| Mar 2017 | - | -$14.41 M(+79.6%) | -$22.34 M(+142.1%) |
| Dec 2016 | -$9.23 M(-81.5%) | -$8.03 M(-30.6%) | -$9.23 M(+0.2%) |
| Sep 2016 | - | -$11.56 M(-199.1%) | -$9.21 M(+48.9%) |
| Jun 2016 | - | $11.66 M(-994.2%) | -$6.19 M(-86.7%) |
| Mar 2016 | - | -$1.30 M(-83.7%) | -$46.44 M(-7.1%) |
| Dec 2015 | -$49.97 M(+130.5%) | -$8.01 M(-6.2%) | -$49.98 M(-5.1%) |
| Sep 2015 | - | -$8.54 M(-70.1%) | -$52.65 M(+4.0%) |
| Jun 2015 | - | -$28.59 M(+491.0%) | -$50.62 M(+104.7%) |
| Mar 2015 | - | -$4.84 M(-54.7%) | -$24.73 M(+14.0%) |
| Dec 2014 | -$21.68 M(+526.5%) | -$10.69 M(+64.2%) | -$21.68 M(+97.2%) |
| Sep 2014 | - | -$6.51 M(+141.4%) | -$11.00 M(+144.9%) |
| Jun 2014 | - | -$2.70 M(+50.2%) | -$4.49 M(+150.2%) |
| Mar 2014 | - | -$1.79 M | -$1.79 M |
| Dec 2013 | -$3.46 M | - | - |
FAQ
- What is Zevra Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Zevra Therapeutics?
- What is Zevra Therapeutics annual EBITDA year-on-year change?
- What is Zevra Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Zevra Therapeutics?
- What is Zevra Therapeutics quarterly EBITDA year-on-year change?
- What is Zevra Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Zevra Therapeutics?
- What is Zevra Therapeutics TTM EBITDA year-on-year change?
What is Zevra Therapeutics annual EBITDA?
The current annual EBITDA of ZVRA is -$43.54 M
What is the all time high annual EBITDA for Zevra Therapeutics?
Zevra Therapeutics all-time high annual EBITDA is -$3.46 M
What is Zevra Therapeutics annual EBITDA year-on-year change?
Over the past year, ZVRA annual EBITDA has changed by -$18.02 M (-70.58%)
What is Zevra Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ZVRA is -$29.30 M
What is the all time high quarterly EBITDA for Zevra Therapeutics?
Zevra Therapeutics all-time high quarterly EBITDA is $11.66 M
What is Zevra Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ZVRA quarterly EBITDA has changed by -$10.95 M (-59.66%)
What is Zevra Therapeutics TTM EBITDA?
The current TTM EBITDA of ZVRA is -$78.22 M
What is the all time high TTM EBITDA for Zevra Therapeutics?
Zevra Therapeutics all-time high TTM EBITDA is $206.00 K
What is Zevra Therapeutics TTM EBITDA year-on-year change?
Over the past year, ZVRA TTM EBITDA has changed by -$34.68 M (-79.65%)